Mark Jit (@markjit) 's Twitter Profile
Mark Jit

@markjit

Modeller, epidemiologist, economist at @LSHTM, visiting prof at @HKUniversity, previously at Public Health England. Interested in vaccines, infectious diseases.

ID: 23673550

linkhttps://www.lshtm.ac.uk/aboutus/people/jit.mark calendar_today10-03-2009 22:42:06

116 Tweet

1,1K Followers

176 Following

Mark Jit (@markjit) 's Twitter Profile Photo

Really important study looking at what-if scenarios about COVID-19 vaccination in Africa led by Yang ๅˆ˜ๆ‰ฌ with great input from Africa CDC and other colleagues!

Mark Jit (@markjit) 's Twitter Profile Photo

A successful GBS vaccine could create billions of $ in value and save 10,000s of lives each year, if prices allow equitable global access.

Rebecca Clark (@ra_clark18) 's Twitter Profile Photo

The first paper for my PhD thesis is now available at The Lancet Global Health! ๐ŸŽ‰ Our modelling shows that introducing new #TB #vaccines are likely to have a substantial health impact in LMICs ๐Ÿ—บ๏ธ๐Ÿฆ ๐Ÿ’‰ From LSHTM TB Modelling Group LSHTM TB Centre Vaccine Centre CMMID London School of Hygiene & Tropical Medicine thelancet.com/journals/langlโ€ฆ

BMC Medicine (@bmcmedicine) 's Twitter Profile Photo

Research by Waterlow et al. finds that next-generation vaccines may offer a cost-effective intervention to reduce influenza burden in low-income countries with year-round seasonality. London School of Hygiene & Tropical Medicine Naomi Waterlow Read more about this modelling study here: bmcmedicine.biomedcentral.com/articles/10.11โ€ฆ

Research by Waterlow et al. finds that next-generation vaccines may offer a cost-effective intervention to reduce influenza burden in low-income countries with year-round seasonality. 
<a href="/LSHTM/">London School of Hygiene & Tropical Medicine</a> <a href="/N_R_Waterlow/">Naomi Waterlow</a> 
Read more about this modelling study here:
bmcmedicine.biomedcentral.com/articles/10.11โ€ฆ
Hugo C Turner (@hugocturner) 's Twitter Profile Photo

1) In our recent review we introduce what are economic costs and why they are used in health economic studies Laura Downey Anna Vassall HITAP Mark Jit resource-allocation.biomedcentral.com/articles/10.11โ€ฆ

Mark Jit (@markjit) 's Twitter Profile Photo

This new collection we put together shows most RSV burden is in very young infants in KE and ZA. So new RSV vaccines and mAbs could be even more cost-effective in some LMICs than recognised. Results of tremendous work by NICD Kenya Medical Research Institute PATH London School of Hygiene & Tropical Medicine investigators.

Mark Jit (@markjit) 's Twitter Profile Photo

I'm delighted and humbled by this news. The award is really a testament to the dedication of my colleagues at LSHTM and around the world. I am so grateful for your support, encouragement and inspiration throughout my journey. Thank you!

Mark Jit (@markjit) 's Twitter Profile Photo

Fantastic that The Economist are highlighting the global disparities around HPV vaccine uptake as well as the opportunity we have to end cervical cancer as public health problem.

Mark Jit (@markjit) 's Twitter Profile Photo

Great that WHO's Full Value of Vaccines Assessment framework is now published in BMC Medicine . This has been used by WHO + collaborators to assess many recent vaccines in development. rdcu.be/df00V

Mark Jit (@markjit) 's Twitter Profile Photo

SIAs reach more unvaccinated children but MCV2 is more efficient per dose at preventing measles cases. New VIMC DynaMICE measles modelling paper in The Lancet Global Health from Megan Auzenbergs, Han Fu and others in @cmmid exploring optimal vaccine strategies: sciencedirect.com/science/articlโ€ฆ

Mark Jit (@markjit) 's Twitter Profile Photo

We are still far from reaching WHO's target of bringing HPV vaccines to 90% of girls before age 15. Excited by opportunities that 1-dose vaccine schedules offer to help bring HPV vaccines to more people. This paper led by Kiesha Prem is a key piece of evidence to inform this.

Naomi Waterlow (@n_r_waterlow) 's Twitter Profile Photo

Thanks to co-authors Simon Procter, Edwin van Leeuwen, Sreejith Radhakrishnan, Mark Jit and Dr Roz Eggo! Also for a fuller understanding of the cost-effectiveness of such vaccines check out our other paper, answering similar questions in a completely different setting! bmcmedicine.biomedcentral.com/articles/10.11โ€ฆ

CMMID (@cmmid_lshtm) 's Twitter Profile Photo

๐Ÿ†• study in BMJ Global Health suggests introducing microarray patches into #immunisation programmes in LMICs could โฌ‡๏ธ decrease #measles burden & prevent high treatment costs. Find out more ๐Ÿ‘‡ bit.ly/3SENs32

๐Ÿ†• study in <a href="/GlobalHealthBMJ/">BMJ Global Health</a> suggests introducing microarray patches into #immunisation programmes in LMICs could โฌ‡๏ธ decrease #measles burden &amp; prevent high treatment costs. 

Find out more ๐Ÿ‘‡
bit.ly/3SENs32
EUROGIN Conference (@euroginhpv) 's Twitter Profile Photo

Join #EUROGIN2024 for a pivotal session on 'One-Dose Vaccination: Evidence Gaps & Global Experiences' ๐Ÿ’‰Discuss dosing plans & advances in #hpvvaccine. with Mark Jit & Marc Brisson ow.ly/gvIX50Qj7Zx #hpvvirus #hpvcongress #hpvawareness #cervicalcancerawareness #Eurogin

Join #EUROGIN2024 for a pivotal session on 'One-Dose Vaccination: Evidence Gaps &amp; Global Experiences' ๐Ÿ’‰Discuss dosing plans &amp; advances in #hpvvaccine. with <a href="/markjit/">Mark Jit</a> &amp; <a href="/brisson__marc/">Marc Brisson</a>

ow.ly/gvIX50Qj7Zx

#hpvvirus #hpvcongress #hpvawareness #cervicalcancerawareness #Eurogin
Richard White (@richardwhite321) 's Twitter Profile Photo

We asked a range of key decision-makers what they need to know to about potential new vaccines The results were..... Alot, and WHO's Full Value of Vaccine Assessments framework helps But FVVAs could be even more useful Our new paper gives 3 ways FVVAs could be even better:

We asked a range of key decision-makers what they need to know to about potential new vaccines

The results were..... Alot, and WHO's Full Value of Vaccine Assessments framework helps

But FVVAs could be even more useful

Our new paper gives 3 ways FVVAs could be even better:
London School of Hygiene & Tropical Medicine (@lshtm) 's Twitter Profile Photo

Vaccines saved 154 million lives over past 50 years study in The Lancet by World Health Organization (WHO) & LSHTM experts estimates. @MarkJit comments on the global success of the Expanded Programme on #Immunization (EPI) ๐ŸŒ๐Ÿ’‰ More ๐Ÿ‘‰bit.ly/4dzKt46

Vaccines saved 154 million lives over past 50 years study in <a href="/TheLancet/">The Lancet</a> by <a href="/WHO/">World Health Organization (WHO)</a> &amp; LSHTM experts estimates.

@MarkJit comments on the global success of the Expanded Programme on #Immunization (EPI) ๐ŸŒ๐Ÿ’‰

More ๐Ÿ‘‰bit.ly/4dzKt46